Digestive Diseases and Sciences

, Volume 56, Issue 2, pp 545–554 | Cite as

Performance Parameters of the Conventional Serological Markers for Autoimmune Hepatitis

  • Albert J. Czaja
Original Article



Autoimmune hepatitis is defined by a conventional battery of autoantibodies that may also be present in other liver diseases.


To define the performance parameters of the conventional autoantibodies for autoimmune hepatitis, determine the diagnostic implications of simultaneous autoantibody production, and assess the performances of serological assays based on indirect immunofluorescence and enzyme immunoassay.


In this study, 265 adults satisfying codified criteria for autoimmune hepatitis and 342 adults who satisfied conventional diagnostic criteria for another chronic liver disease were each assessed for the conventional autoantibodies.


Antinuclear antibodies, smooth muscle antibodies, and antibodies to liver kidney type 1 had sensitivities of only 32, 16, and 1%, respectively, for the diagnosis of autoimmune hepatitis, and their diagnostic accuracy ranged from 56 to 61%. The combination of antinuclear antibodies and smooth muscle antibodies at presentation had superior sensitivity (43%), specificity (99%), positive (97%) and negative (69%) predictabilities, and diagnostic accuracy (74%) than each marker alone. The occurrence of multiple autoantibodies was lower in other chronic liver diseases than in autoimmune hepatitis (8% versus 51%, p < 0.000001). The enzyme immunoassay for antinuclear antibodies had an accuracy that was not discriminative for autoimmune hepatitis (p = 0.06).


Isolated autoantibodies have a low diagnostic accuracy for autoimmune hepatitis. Concurrent antinuclear antibodies and smooth muscle antibodies have superior performance parameters. The enzyme immunoassay for antinuclear antibodies performs less well than the assay based on indirect immunofluorescence.


Autoantibodies Diagnosis Performance Assays Autoimmune hepatitis 


Conflict of interest

This work did not receive financial support from a funding agency or institution, and Albert J. Czaja, MD has no conflict of interests to declare.


  1. 1.
    Manns MP, Czaja AJ, Gorham JD, et al. Practice guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.PubMedGoogle Scholar
  2. 2.
    Lindor KD, Gershwin ME, Poupon R, et al. AASLD practice guidelines. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.CrossRefPubMedGoogle Scholar
  3. 3.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology. 1995;108:157–164.CrossRefPubMedGoogle Scholar
  4. 4.
    Laskin CA, Vidins E, Blendis LM, Soloninka CA. Autoantibodies in alcoholic liver disease. Am J Med. 1990;89:129–133.CrossRefPubMedGoogle Scholar
  5. 5.
    Loria P, Lonardo A, Leonardi F, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci. 2003;48:2173–2181.CrossRefPubMedGoogle Scholar
  6. 6.
    Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2004;99:1316–1320.CrossRefPubMedGoogle Scholar
  7. 7.
    Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol. 2004;38:801–804.CrossRefPubMedGoogle Scholar
  8. 8.
    Bernstein RM, Neuberger JM, Bunn CC, et al. Diversity of autoantibodies in primary biliary cirrhosis and chronic active hepatitis. Clin Exp Immunol. 1984;55:553–560.PubMedGoogle Scholar
  9. 9.
    Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology. 1996;23:1369–1376.CrossRefPubMedGoogle Scholar
  10. 10.
    Czaja AJ, Santrach PJ, Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci. 2001;46:140–147.CrossRefPubMedGoogle Scholar
  11. 11.
    Lunel F, Abuaf N, Frangeul L, et al. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology. 1992;16:630–636.CrossRefPubMedGoogle Scholar
  12. 12.
    Abuaf N, Lunel F, Giral P, et al. Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol. 1993;18:359–364.CrossRefPubMedGoogle Scholar
  13. 13.
    Leung PS, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology. 2007;46:1436–1442.CrossRefPubMedGoogle Scholar
  14. 14.
    O’Brien C, Joshi S, Feld JJ, et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology. 2008;48:550–556.CrossRefPubMedGoogle Scholar
  15. 15.
    Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol. 2008;42:1047–1053.CrossRefPubMedGoogle Scholar
  16. 16.
    Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996;125:588–598.PubMedGoogle Scholar
  17. 17.
    Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28:360–365.CrossRefPubMedGoogle Scholar
  18. 18.
    Heathcote J. Variant syndromes of autoimmune hepatitis. Clin Liver Dis. 2002;6:669–684.CrossRefPubMedGoogle Scholar
  19. 19.
    Czaja AJ. Variant forms of autoimmune hepatitis. Curr Gastroenterol Rep. 1999;1:63–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut. 2001;49:589–594.CrossRefPubMedGoogle Scholar
  21. 21.
    Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.CrossRefPubMedGoogle Scholar
  22. 22.
    Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.CrossRefPubMedGoogle Scholar
  23. 23.
    Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540–1548.CrossRefPubMedGoogle Scholar
  24. 24.
    Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut. 1998;42:721–726.CrossRefPubMedGoogle Scholar
  25. 25.
    Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394–401.CrossRefPubMedGoogle Scholar
  26. 26.
    Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol. 2003;37:315–329.CrossRefPubMedGoogle Scholar
  27. 27.
    Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol. 2006;2:33–48.CrossRefPubMedGoogle Scholar
  28. 28.
    Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology. 1992;103:1290–1295.PubMedGoogle Scholar
  29. 29.
    Czaja AJ, Freese DK. Practice guidelines of the American Association for the Study of Liver Diseases. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479–497.CrossRefPubMedGoogle Scholar
  30. 30.
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.CrossRefPubMedGoogle Scholar
  31. 31.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.CrossRefPubMedGoogle Scholar
  32. 32.
    Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824–1832.PubMedGoogle Scholar
  33. 33.
    Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–678.PubMedGoogle Scholar
  34. 34.
    Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265–278.CrossRefPubMedGoogle Scholar
  35. 35.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 1998;29:198–206.CrossRefPubMedGoogle Scholar
  36. 36.
    O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010;51:307–328.PubMedGoogle Scholar
  37. 37.
    Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology. 2001;120:239–249.CrossRefPubMedGoogle Scholar
  38. 38.
    Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci. 1997;42:1688–1696.CrossRefPubMedGoogle Scholar
  39. 39.
    Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med. 1998;122:993–999.PubMedGoogle Scholar
  40. 40.
    Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol. 1995;90:1206–1211.PubMedGoogle Scholar
  41. 41.
    Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology. 1987;7:1333–1339.CrossRefPubMedGoogle Scholar
  42. 42.
    Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 1991;88:1370–1378.CrossRefPubMedGoogle Scholar
  43. 43.
    Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology. 1993;105:1522–1528.PubMedGoogle Scholar
  44. 44.
    Mishima S, Omagari K, Ohba K, et al. Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study. Hepatogastroenterology. 2008;55:221–227.PubMedGoogle Scholar
  45. 45.
    Nezu S, Tanaka A, Yasui H, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol. 2006;21:1448–1454.PubMedGoogle Scholar
  46. 46.
    Miyakawa H, Kikuchi K, Jong-Hon K, et al. High sensitivity of a novel ELISA for anti-M2 in primary biliary cirrhosis. J Gastroenterol. 2001;36:33–38.CrossRefPubMedGoogle Scholar
  47. 47.
    Dahnrich C, Pares A, Caballeria L, et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem. 2009;55:978–985.CrossRefPubMedGoogle Scholar
  48. 48.
    Liu H, Norman GL, Shums Z, et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;(Epub ahead of print).Google Scholar
  49. 49.
    Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis. 1997;17:79–90.CrossRefPubMedGoogle Scholar
  50. 50.
    Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med. 2008;8:9–15.CrossRefPubMedGoogle Scholar
  51. 51.
    Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144–2161.CrossRefPubMedGoogle Scholar
  52. 52.
    Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging. 2008;25:219–239.CrossRefPubMedGoogle Scholar
  53. 53.
    Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:2051–2057.CrossRefPubMedGoogle Scholar
  54. 54.
    Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci. 1998;43:2149–2155.CrossRefPubMedGoogle Scholar
  55. 55.
    Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.CrossRefPubMedGoogle Scholar
  56. 56.
    Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology. 1994;107:200–207.PubMedGoogle Scholar
  57. 57.
    Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the international autoimmune hepatitis group. J Hepatol. 2004;41:677–683.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA

Personalised recommendations